The lower incidence of poor binders for SARS-CoV-2 peptides in COVID-19 severe patients, including HLA-Bw4 weak binders and HLA-B*46:01 alone, raises the possibility that the reduced SARS-CoV-2 antigen-presenting capacity by some HLA-I allotypes encoding KIR binding motifs might be compensated by their role in NK cell licensing. Here, HLA-B is linked to COVID-19.